Samuel Gandy, MD, PhD, an internationally recognized expert in Alzheimer's pathology and drug discovery, directs the extensive Alzheimer's research program at Farber, which includes three of the first anti-amyloid clinical trials in North America. He has been PI on a 15-year NIA-funded program in Alzheimer's drug discovery. Other basic research programs include a-beta metabolism; APP molecular biology; presenilin and apoliprotein neurobiology; isoprostanes; hormonal influences on a-beta formation, and the role of statins in alpha secretase activation. His laboratory is developing primate models of amyloidogenesis and has recently published results of a-beta vaccination in rhesus monkeys.
- Director, Farber Institute for Neurosciences
- Professor, Department of Neurology
- Professor, Department of Biochemistry and Molecular Pharmacology
- Vice Chair, National Medical and Scientific Advisory Council, Alzheimer's Association
Learn more about Dr. Gandy...
USA Today article: Memory loss: Samuel Gandy, M.D.
Thoman Jefferson University Hospital Press Release: Jefferson Scientists Discover Mechanism Tying Obesity to Alzheimer’s Disease
Thomas Jefferson University Faculty Profile: Samuel Gandy
Past Forum speaker bios